Case 77 – summary

Case 77 Summary

 

Thanks to everyone who contributed to the case this week.

 

Our case started with a blood film to test our morphology skills.  We picked up that the blood film showed:

  • Dysplastic neutrophils
  • Blasts
  • NRBCs
  • Tear drop poikilocytes
  • Thrombocytopenia

IMG_2154

The FBC indices identified that the patient was anaemic, thrombocytopenic and neutropenic.  The initial response to these bloods should be to ensure the safety of the patient – i.e. evidence of bleeding/sepsis/ symptomatic anaemia.  As a haematologist reviewing the blood film I would also look for any previous results on the system for this patient or clinic letter i.e. was he known to haematology already.    Urgent discussion with GP is required if these are new findings to ensure they are aware of the results, and allow the GP to make a judgement on the clinical symptoms and whether urgent haematology review is required.  If the patient is symptomatic he should be admitted to hospital urgently.  However if he remains relatively stable, he could be assess as an outpatient on an urgent basis.

 

The next step was a bone marrow marrow biopsy.  In real life we would also suggest checking haematinics/medication history/review comorbidities.  We requested a coagulation screen also for this patient which I think is useful, specifically if he was bleeding, given the thrombocytopenia.  A clotting may also be useful if we felt this picture may have developed due to an underlying sepsis so ensure there was no evidence of DIC.

 

The bone marrow showed evidence of dysplasia and 13% blast count.  Previous diagnostic criteria would have classified this as RAEB-2, however WHO classification has recently been revised and the diagnosis would be MDS-EB-2

 

WHO classification for MDS 2016.

PB and BM findings and cytogenetics of MDS

Name Dysplastic lineages Cytopenias* Ring sideroblasts as % of marrow erythroid elements BM and PB blasts Cytogenetics by conventional karyotype analysis
MDS with single lineage dysplasia (MDS-SLD) 1 1 or 2 <15%/<5% BM <5%, PB <1%, no Auer rods Any, unless fulfills all criteria for MDS with isolated del(5q)
MDS with multilineage dysplasia (MDS-MLD) 2 or 3 1-3 <15%/<5% BM <5%, PB <1%, no Auer rods Any, unless fulfills all criteria for MDS with isolated del(5q)
MDS with ring sideroblasts (MDS-RS)
 MDS-RS with single lineage dysplasia (MDS-RS-SLD) 1 1 or 2 ≥15%/≥5% BM <5%, PB <1%, no Auer rods Any, unless fulfills all criteria for MDS with isolated del(5q)
 MDS-RS with multilineage dysplasia (MDS-RS-MLD) 2 or 3 1-3 ≥15%/≥5% BM <5%, PB <1%, no Auer rods Any, unless fulfills all criteria for MDS with isolated del(5q)
MDS with isolated del(5q) 1-3 1-2 None or any BM <5%, PB <1%, no Auer rods del(5q) alone or with 1 additional abnormality except −7 or del(7q)
MDS with excess blasts (MDS-EB)
 MDS-EB-1 0-3 1-3 None or any BM 5%-9% or PB 2%-4%, no Auer rods Any
 MDS-EB-2 0-3 1-3 None or any BM 10%-19% or PB 5%-19% or Auer rods Any
MDS, unclassifiable (MDS-U)
 with 1% blood blasts 1-3 1-3 None or any BM <5%, PB = 1%,no Auer rods Any
 with single lineage dysplasia and pancytopenia 1 3 None or any BM <5%, PB <1%, no Auer rods Any
 based on defining cytogenetic abnormality 0 1-3 <15%§ BM <5%, PB <1%, no Auer rods MDS-defining abnormality
Refractory cytopenia of childhood 1-3 1-3 None BM <5%, PB <2% Any

 

 

Assessing risk

Once the patient has been diagnosed, we need to be able to assess the patients isk in order to develop an optimal management plan for that individual.  Important factors to take into account are the patients age, co-morbidities and ECOG status, as these will potential affect the type of treatment appropriate for each individual patient.

IPSS-R is a decision support tool designed to assess risk of disease and therefore prognosis based on blood indices, cytogenetics, and blast count.

 

IPSS-R Cytogenetic risk groups*,**

Cytogenetic prognostic subgroups Cytogenetic abnormalities
Very good -Y, del(11q)
Good Normal, del(5q), del(12p), del(20q), double including del(5q)
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones
Poor -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities
Very poor Complex: >3 abnormalities

IPSS-R Prognostic Score Values*

Prognostic variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very Good Good Intermediate Poor Very Poor
BM Blast % <=2 >2-<5% 5-10% >10%
Hemoglobin =>10 8-<10 <8
Platelets =>100 50-<100 <50
ANC =>0.8 <0.8  

 

IPSS-R Prognostic Risk Categories/Scores*

RISK CATEGORY RISK SCORE
Very Low <=1.5
Low >1.5 – 3
Intermediate >3 – 4.5
High >4.5 – 6
Very High >6

IPSS-R: Prognostic Risk Category Clinical Outcomes*

No. pts Very Low Low Intermediate High Very High
Patients (%) 7012 19% 38% 20% 13% 10%
Survival*** 8.8 5.3 3.0 1.6 0.8
AML/25%***,^ NR 10.8 3.2 1.4 0.7

 

Somatic mutation profile was also suggested by one of our followers.  This can also help provide prognostic information and risk stratification, but has not been incorporated into the IPPS-R scoring system currently.  Somatic mutations in MDS driver genes especially TP53, ASXL1, DNMT3A, EZH2, and RUNX1, are associated with poorer outcomes and have been shown to add independent prognostic information.  The number and types of specific mutations are strongly associated with disease outcome in MDS, and the addition of mutation data improves the prognostic value of existing risk-stratification schemes in MDS.

 

Approach to treatment

The patient in this case would be classified as very high risk disease given his IPSS-R score.  Given his age and relative fitness, the approach of transplant should be considered.  Options pre-transplant which were suggested included azacitidine, and AML – type chemo (AML 18 and AML 19 are trials currently available in the UK and would be options for this patient).  Discussion with the transplant team is important early, as some patient may be consider for transplants upfront if donors were available.

 

 

References:

  1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.  Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola and James W. Vardiman

Blood 2016 127:2391-2405; doi: https://doi.org/10.1182/blood-2016-03-643544

  1. Recent developments in myelodysplastic syndromes

Rafael Bejar and David P. Steensma

Blood 2014 124:2793-2803; doi: https://doi.org/10.1182/blood-2014-04-522136

  1. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator. International working group for the prognosis of MDS.  http://ipss-r.com/
  2. How I treat patients with myelodysplastic syndromes

    Richard M. Stone

 

About TeamHaem

Online education and discussion about all things haematological
This entry was posted in Acute leukaemia, Bone marrow failure and tagged , , , , , . Bookmark the permalink.